College of Agriculture

Permanent URI for this communityhttps://scholarworks.montana.edu/handle/1/4

As the foundation of the land grant mission at Montana State University, the College of Agriculture and the Montana Agricultural Experiment Station provide instruction in traditional and innovative degree programs and conduct research on old and new challenges for Montana’s agricultural community. This integration creates opportunities for students and faculty to excel through hands-on learning, to serve through campus and community engagement, to explore unique solutions to distinct and interesting questions and to connect Montanans with the global community through research discoveries and outreach.

Browse

Filters

20221

Settings

Author: search.filters.author.Blackwell, KarlinSubject: search.filters.subject.inflammation

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    An ADAM17-Neutralizing Antibody Reduces Inflammation and Mortality While Increasing Viral Burden in a COVID-19 Mouse Model
    (Frontiers Media SA, 2022-06) Hedges, Jodi F.; Snyder, Deann T.; Robison, Amanda; Grifka-Walk, Heather M.; Blackwell, Karlin; Shepardson, Kelly; Kominsky, Douglas; Rynda-Apple, Agnieszka; Walcheck, Bruce; Jutila, Mark A.
    Angiotensin Converting Enzyme 2 (ACE2) is the primary cell entry receptor for SARS-CoV and SARS-CoV-2 viruses. A disintegrin and metalloproteinase 17 (ADAM17) is a protease that cleaves ectodomains of transmembrane proteins, including that of ACE2 and the proinflammatory cytokine TNF-α, from cell surfaces upon cellular activation. We hypothesized that blockade of ADAM17 activity would alter COVID-19 pathogenesis. To assess this pathway, we blocked the function of ADAM17 using the monoclonal antibody MEDI3622 in the K18-hACE2 transgenic mouse model of COVID-19. Antibody-treated mice were healthier, less moribund, and had significantly lower lung pathology than saline-treated mice. However, the viral burden in the lungs of MEDI3622-treated mice was significantly increased. Thus, ADAM17 appears to have a critical anti-viral role, but also may promote inflammatory damage. Since the inflammatory cascade is ultimately the reason for adverse outcomes in COVID-19 patients, there may be a therapeutic application for the MEDI3622 antibody.
Copyright (c) 2002-2022, LYRASIS. All rights reserved.